The SCLC TME has previously been characterized in non-immune (CD45-) cells,9 circulating tumor cells (CTCs),26 CTC-derived xenografts,10 and limited patient tumor/adjacent normal tissue samples (n=11).11 We further characterize the SCLC TME in our cohort. The gene discussed is PTPRC; the disease is neoplasm.